RECORD // Company

Passage BIO, Inc.

Built 2026-11-22T00:18:52Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Passage Bio, Inc. · Ctgov · same registered legal name as 'Passage BIO, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-10 · accession 0001104659-26-124783

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-4,719,0003 months ended 2026-09-3010-Q2026-11-100001104659-26-1247832026-11-22 00:18 UTCReport an error
Cash and cash equivalents$20,160,000at 2026-09-3010-Q2026-11-100001104659-26-1247832026-11-22 00:18 UTCReport an error
Contract liabilities, current$17,027,000at 2026-09-3010-Q2026-11-100001104659-26-1247832026-11-22 00:18 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001787297
Ticker
PASG
EIN
822729751
CUSIP
702712209
Record ID
sx:sec:0001787297

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

33 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-19SEC EDGAR company profile2026-11-22 00:18 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-19SEC EDGAR company profile2026-11-22 00:18 UTCReport an error
State of incorporationDE2026-11-19SEC EDGAR company profile2026-11-22 00:18 UTCReport an error
Fiscal year end (MMDD)12312026-11-19SEC EDGAR company profile2026-11-22 00:18 UTCReport an error
Business addressONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA, PA, 191032026-11-19SEC EDGAR company profile2026-11-22 00:18 UTCReport an error
ExchangesNasdaq2026-11-19SEC EDGAR company profile2026-11-22 00:18 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-45,522,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:18 UTCReport an error
Total assets (at 2025-12-31)$62,281,0002025-12-3110-K, XBRL Assets2026-11-22 00:18 UTCReport an error
Stockholders' equity (at 2025-12-31)$18,755,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:18 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$46,303,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:18 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-31,509,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:18 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2024-12-31)$34,0002024-12-3110-K, XBRL PaymentsToAcquireProductiveAssets2026-11-22 00:18 UTCReport an error
Operating lease liabilities (at 2025-12-31)$24,010,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 00:18 UTCReport an error
Form D total offering amount (D filed 2019-09-06)$110,000,0002019-09-06D2026-11-22 00:18 UTCReport an error
Form D total amount sold (D filed 2019-09-06)$109,999,9742019-09-06D2026-11-22 00:18 UTCReport an error
Form D industry groupOther Health Care2019-09-06D2026-11-22 00:18 UTCReport an error
Form D revenue rangeDecline to Disclose2019-09-06D2026-11-22 00:18 UTCReport an error
Form D date of first sale2019-08-212019-09-06D2026-11-22 00:18 UTCReport an error
8-K Item 8.01 (filed 2026-11-19)Other Events. As previously disclosed, on November 5, 2026, Passage Bio, Inc. (“Passage Bio”) held a Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, Passage Bio’s stockholders considered and approved proposals which related to the Amended and Restated Agreement and Plan of Merger by and among Passage Bio, Peregrine Merger Sub, Inc., Peregrine Merger Sub II, LLC, and Remix Therapeutics, Inc. (“Remix”), dated as of September 2, 2026, and further amended on October 5, 2026 (the “Merger Agreement”), pursuant to which, among other matters, Peregrine Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Passage Bio (“Merger Sub”), will merge with…2026-11-19SEC EDGAR 8-K 0001140361-26-044947 (text as filed, excerpt)2026-11-22 00:18 UTCReport an error
8-K Item 7.01 (filed 2026-11-19)Regulation FD Disclosure On November 19, 2026, Remix Therapeutics, Inc. (“Remix”) issued a press release announcing updated Phase 1 data from its ongoing ARIA Phase 1/2 clinical trial of REM-422, an oral MYB mRNA degrader, in patients with adenoid cystic carcinoma (“ACC”), in a late-breaking oral presentation at the 2026 EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the…2026-11-19SEC EDGAR 8-K 0001140361-26-044811 (text as filed, excerpt)2026-11-22 00:18 UTCReport an error
8-K Item 3.01 (filed 2026-11-18)Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 12, 2026, Passage Bio, Inc. (“Passage Bio” or the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying it that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. In its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, Passage Bio reported stockholders’ equity of $50,000, and, as of November 12, 2026, Passage Bio…2026-11-18SEC EDGAR 8-K 0001140361-26-044734 (text as filed, excerpt)2026-11-22 00:18 UTCReport an error
8-K Item 5.02 (filed 2026-11-06)Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 2026 Equity Incentive Plan On November 5, 2026, Passage Bio, Inc. (“Passage Bio”) held a Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, Passage Bio’s stockholders considered and approved the Remix Therapeutics, Inc. (“Remix”) 2026 Equity Incentive Plan (the “2026 Plan”), which will become effective at the effective time of the First Merger (as defined below) (the “Initial Effective Time”) and is contingent on the completion of the First Merger. The 2026 Plan is intended to replace Passage Bio’s 2018 Equity…2026-11-06SEC EDGAR 8-K 0001140361-26-042222 (text as filed, excerpt)2026-11-22 00:18 UTCReport an error
8-K Item 5.07 (filed 2026-11-06)Submission of Matters to a Vote of Security Holders. On November 5, 2026, at the Special Meeting, Passage Bio’s stockholders considered and voted on the proposals set forth below, which relate to the Amended and Restated Agreement and Plan of Merger by and among Passage Bio, Peregrine Merger Sub, Inc., Peregrine Merger Sub II, LLC and Remix, dated as of September 2, 2026, and further amended on October 5, 2026 (the “Merger Agreement”), pursuant to which, among other matters, Peregrine Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Passage Bio (“Merger Sub”), will merge with and into Remix, with Remix surviving as a wholly owned subsidiary of Passage Bio (the “First…2026-11-06SEC EDGAR 8-K 0001140361-26-042222 (text as filed, excerpt)2026-11-22 00:18 UTCReport an error
Largest institutional holder #1 (13F as filed): CITADEL ADVISORS LLC$4,307,1352026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #2 (13F as filed): Lynx1 Capital Management LP$3,287,9422026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #3 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$556,1442026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #4 (13F as filed): Balyasny Asset Management L.P.$522,2822026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #5 (13F as filed): Ikarian Capital, LLC$485,6432026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #6 (13F as filed): Yiheng Capital Management, L.P.$420,1532026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #7 (13F as filed): RENAISSANCE TECHNOLOGIES LLC$233,7132026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #8 (13F as filed): Erste Asset Management GmbH$197,2252026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #9 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$180,7162026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #10 (13F as filed): Verdad Advisers, LP$149,9532026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.